The Therapeutic Goods Administration (TGA) has issued a new safety advisory for Strattera, the non-stimulant drug once touted as a safe alternative to ADHD stimulants. Strattera already carries warnings for serious adverse events including suicidal ideation and potential fatal liver damage. The TGA has now added a warning about ‘clinically significant increases in heart rate and blood pressure’. (The new warning is available at http://www.tga.gov.au/safety/alerts-medicine-atomoxetine-111102.htm)
You are currently browsing articles tagged Strattera heart risk.
Recent Comments